Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...

Eli Lilly LLY-2.61%decrease; red down pointing triangle reported higher third-quarter profit and raised its full-year outlook on surging demand for its GLP-1 weight-loss drugs, sending its shares ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly ...

Oct 28 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it was collaborating with Nvidia (NVDA.O), opens new tab to build a supercomputer to help with drug discovery and shorten ...

Eli Lilly announced a partnership with chipmaker NVIDIA on Tuesday to build what it claims will be the “most powerful supercomputer owned and operated by a pharmaceutical company.” Lilly’s technology ...

Eli Lilly (NYSE:LLY) on Friday reported plans to acquire Adverum Biotechnologies (NASDAQ:ADVM) and its lead gene therapy candidate, Ixo-vec, sending Adverum shares soaring in premarket trading. Under ...